Consistent with our previous in vitro findings, we also observed a marked decrease in MYCN and Ki-67 proteins in the tumors of the combination group (Fig. 6J and K), Taken together, these results suggested that m6A modification is a potential therapeutic target for NB. This evidence concerns the gene MYCN and neuroblastoma.